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Leukemogenesis: Small differences in Myb have large effects
Thomas Graf
The avian retroviruses E26 and AMV carry mutated
versions of the gene encoding the cellular transcription
factor c-Myb. Surprisingly, these two mutant forms of
Myb differ in the subsets of myeloid cells that they
transform, the target genes that they activate, and the
way in which they are regulated.
Address: EMBL, Meyerhofstrasse 1, 69117 Heidelberg, Germany.
E-mail: graf@embl-heidelberg.de
Current Biology 1998, 8:R353–R355
http://biomednet.com/elecref/09609822008R0353
© Current Biology Ltd ISSN 0960-9822
What happens in leukemia when differentiation is
blocked and cells proliferate in an uncontrolled fashion?
This question has been extensively studied using onco-
gene-containing retroviruses. About a dozen of these
viruses that cause specific types of acute leukemia and
transform corresponding blood cells in culture have now
been isolated. Isolates from viruses that contain the same
oncogene have been widely assumed to transform cells by
a common mechanism. E26 and avian myeloblastosis virus
(AMV), two leukemia viruses that harbor closely related
oncogenes derived from c-myb, appear to transform cells
through different mechanisms, however.
The c-Myb protein is a transcription factor whose DNA-
binding domain contains three homeodomain-like repeats.
It is expressed in immature, proliferating cells of all
hematopoietic lineages: the importance of c-myb in
hematopoiesis is clearly demonstrated by the finding that
c-Myb-deficient mice die in utero due to a lack of definitive
blood cells. Both of the retroviral forms of Myb have trun-
cations which delete negative-regulatory domains found in
c-Myb. In addition, E26-derived Myb (E26-Myb) is fused
to the Ets-1 transcription factor and AMV-derived Myb
(AMV-Myb) contains a number of point mutations, three
of which are located in the DNA-binding domain [1].
E26-transformed and AMV-transformed myeloid cells differ
AMV and E26 transformation results in related, but distin-
guishable, myeloid cells. E26 transforms cells that are
myeloblast-like, can differentiate along both the granulo-
cytic and monocytic lineages, and depend on chicken
myelomonocytic growth factor (cMGF) — a cytokine
related to granulocyte colony-stimulating factor (G-
CSF)/interleukin (IL)-6 — for growth. In contrast, AMV
transforms cells that resemble monoblasts, can be induced
to differentiate into monocytes and macrophages but not
granulocytes, and are cMGF independent producing their
own growth factor [2]. In both cases, the v-Myb proteins do
not merely block differentiation, but also impose an imma-
ture phenotype. Thus, myeloid cells transformed by a tem-
perature-sensitive mutant of E26 can differentiate
reversibly as the oncoprotein is alternately inactivated or re-
activated by changing the temperature. Similarly, a regulat-
able form of AMV-Myb can also induce reversible changes
in morphology and gene expression in myeloid cells [1,3].
Although both E26 and AMV readily transform myeloid
cells in culture, only the latter can cause myeloid
leukemias (E26 can induce a leukemia upon transforma-
tion of multilineage precursors, but this activity requires
fusion of the Myb and Ets proteins [3]). However, a recom-
binant virus expressing E26-Myb together with cMGF
causes an acute promyelocytic leukemia [4]. This demon-
strates that autocrine growth is a prerequisite for the induc-
tion of myeloid leukemias by Myb, and raises the question
of why only AMV-transformed cells produce cMGF.
Differences in target gene activation by E26 and AMV
In spite of their similarity, the Myb proteins from AMV
and E26 activate different target genes. For example, the
mim-1 gene, which encodes a secreted protein related to a
chemotactic factor [5], is activated by the combinatorial
action of either E26-Myb or c-Myb with the basic leucine
zipper (bZip) transcription factors C/EBPα or β [1,3].
However, AMV-Myb does not induce mim-1 expression.
In contrast, AMV-Myb but not E26-Myb activates the
GBX2 gene, which encodes a homeodomain transcription
factor that is expressed in AMV-transformed but not E26-
transformed myeloid cells. This discovery was made by
Kowenz-Leutz et al. [6] who, working backwards from the
promoter of the cMGF gene looking for promoter-binding
proteins, cloned GBX2 as a regulator of cMGF expression
and showed that the ectopic expression of GBX2 in E26-
transformed myeloblasts induces the synthesis of cMGF
and the acquisition of a monoblast-like phenotype. The
phenotypic and leukemogenic differences between AMV-
transformed and E26-transformed cells may therefore boil
down to whether or not each type of Myb protein is able
to activate the expression of GBX2, and ultimately, the
cMGF gene. This aspect of the biology of the two v-Myb
proteins is summarized in Figure 1.
Mutations in AMV-Myb disrupt the binding of Cyp-40
How can two such similar versions of the Myb protein have
such different biological effects? Here, three point muta-
tions in the DNA-binding domain of AMV-Myb seem to be
crucial. Thus, v-Myb constructs containing these mutations
activate GBX2 but not mim-1 expression, whereas Myb 
proteins lacking these mutations (c-Myb and E26-Myb)
activate mim-1 but not GBX2 [2,6,7]. The point mutations
in AMV-Myb do not affect DNA-binding capacity or speci-
ficity but, as they face away from the DNA towards the
solvent, these residues probably form part of a protein
interaction surface [8]. Recent work by Leverson and Ness
[9] has now revealed that a cellular protein, termed Cyp-40,
discriminates between the two forms of Myb. Cyp-40 is a
cyclosporin-A-binding cyclophilin composed of an amino-
terminal peptidyl prolyl isomerase (PPIase) domain and a
carboxy-terminal domain containing tetratricopeptide
repeats (TPRs). The TPR region of Cyp-40 binds to the
E26-Myb/c-Myb DNA-binding domain but not to that of
AMV-Myb. Furthermore, Cyp-40 inhibits the DNA-
binding activity of E26-Myb/c-Myb but not that of AMV-
Myb, and this inhibition can be blocked by cyclosporin A, a
competitive inhibitor of PPIase activity. Although the role
of Cyp-40 in vivo is still unclear, these observations suggest
that AMV-Myb has evolved to escape negative regulation
by cyclophilins. In addition, the Cyp-40 data suggest that
AMV-Myb and E26-Myb proteins might interact with
alternate sets of transcriptional cofactors, leading ultimately
to the induction of different sets of target genes, such as
mim-1 and GBX2. The emerging role of cyclophilins and
other PPIases as regulators of transcription, signal transduc-
tion and cell cycle is the subject of a recent review [10].
Alternate Myb activities and myeloid differentiation
The profound biological differences between E26-Myb/c-
Myb and AMV-Myb suggest that the role of c-Myb in
normal myeloid cell differentiation might involve two 
different active states of the protein. This is supported by
the finding that the inability of E26-Myb/c-Myb to induce
GBX2 expression can be overcome by the activation of
upstream signals. Thus, Ras or tyrosine kinase-type onco-
genes or an activated epidermal growth factor receptor can
each cooperate with E26-Myb/c-Myb to activate GBX2
expression [6]. This suggests that a post-translational modi-
fication enables E26-Myb/c-Myb to interact with a cellular
cofactor and that the mutations in AMV-Myb allow it to
bind to this cofactor constitutively. Therefore, receptor
tyrosine kinases in normal cells might ultimately control the
preference of c-Myb for one set of target genes or the other.
How do these results fit into the regulation of normal
hematopoiesis? The model in Figure 2 proposes that the
transition of a multipotent progenitor into a myeloblast
requires the upregulation of c-Myb and C/EBP(α or β), as
well as the concomitant downregulation of stem-cell-spe-
cific transcription factors. This idea is based on the obser-
vation that E26-transformed multipotent progenitors
upregulate C/EBP and downregulate GATA proteins
when they are induced to differentiate into myeloid cells
or eosinophils [11,12]. Consistent with this proposal,
C/EBPα-deficient mice have a block to the development
of neutrophil and eosinophil granulocytes [13]. The deci-
sion of bipotent progenitors to differentiate into granulo-
cytes might represent a default pathway in which mim-1
expression is maintained, although the activation of other
factors, such as retinoic acid receptors, might still be
required. In contrast, the decision of myeloid progenitors
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Phenotypes of cells transformed by E26-Myb and AMV-Myb in the context of myeloid cell differentiation. White arrows indicate differentiation, and
red and blue arrows indicate self-renewal. Points where v-Myb proteins block differentiation are indicated by red and blue bars.
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to differentiate towards the monocytic lineage requires the
activation of a tyrosine kinase-type receptor and/or the
Ras pathway, resulting in a form of c-Myb that can acti-
vate GBX2. In turn, monoblasts mature into monocytes
and macrophages when the protein kinase C (PKC)
pathway becomes activated, such as after exposure to bac-
terial lipopolysaccharides or phorbol esters.
The model is speculative, as neither the factor that acti-
vates the Ras/PKC pathways in multipotent progenitors to
induce myeloblast differentiation, nor the factor that trig-
gers the Ras pathway in myeloblasts to induce monoblast
differentiation are known. Also, the model does not take
into account several other transcription factors that have
been implicated in the regulation of myeloid-specific
genes such as PU.1, which has been shown to synergize
with C/EBP in the regulation of these genes [13].
Any commonalities left?
The observations discussed suggest that Myb proteins
might have a role as ‘biochemical switches’, interpreting
upstream signals by activating alternate sets of genes. The
mechanism by which either type of v-Myb transforms cells
remains unclear, however. It has been found that both E26-
Myb and c-Myb can upregulate the bcl-2 gene, preventing
myeloid cells and T cells from undergoing programmed cell
death [14,15]. Although this might be an essential step for
cell transformation by E26-Myb, it is not clear whether this
also holds true for AMV-Myb. In addition, perhaps the most
important question that remains to be answered is: how do
Myb proteins prevent myeloid cells from entering cell cycle
withdrawal? Will the two nonidentical twins agree for once
to operate through a common mechanism? My bet is no.
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Figure 2
A model for the role of c-Myb and upstream
signaling pathways in normal granulocyte and
macrophage differentiation. The asterisk
indicates proposed protein modifications.
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